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ABSTRACT 31 
 32 
One of the main pursuits, yet most difficult, in monitoring studies is to identify 33 
the sources of environmental pollution. In this study we have identified, for the 34 
first time, senior residences from south European countries as an important 35 
source of pharmaceuticals in the environment. We have estimated that 36 
compounds released from effluents of senior residences at a concentration of 37 
only 10 µg/L can reach river waters at a concentration higher than 0.01 µg/L, 38 
which is the European Medicines Agency threshold for risk evaluation of 39 
pharmaceuticals in surface waters. This study has been based on 5 40 
establishments for the elder in Portugal, Spain and France, hosting from 52 to 41 
139 patients. We have compiled the pharmaceuticals dispensed on a daily base 42 
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and calculated the consumption rates. Up to 636 g of pharmaceuticals are 43 
consumed daily, being analgesics, antiepileptic, antibiotic, anticonvulsant, 44 
antidiabetic and laxatives the main drugs families administered. According to 45 
excretion rates, dilution in the sewage grid and elimination in wastewater 46 
treatment plants and reported toxicity, amoxilin, glucosamide, ibuprofen, 47 
metformin, paracetamol and megestrol were the compounds bearing the higher 48 
environmental hazards. Finally, we discuss the risk management actions related 49 
to the discharge of pharmaceuticals from senior residences to surface waters.    50 
 51 
Keywords: senior residences; pharmaceuticals; predicted environmental 52 
concentrations; risk management; 10 µg/L. 53 
 54 
Introduction 55 
Water pollution today represents a major challenge both at the economic 56 
and social level. Quality of water must be preserved both for human protection 57 
and to safeguard the environment from compounds capable to exert an effect at 58 
low levels of concentration. Although the Water Framework Directive requires 59 
European countries to control certain compounds classified as "priority 60 
pollutants", monitoring programs have identified a diffuse and persistent 61 
pollution in water due to other compounds. These compounds are the so-called 62 
emerging pollutants and are refractory to traditional wastewater treatment. 63 
Among others, pharmaceuticals are of concern given their high incidence and 64 
global distribution in river waters (Banjac et al. 2015, Zhang et al. 2013). Their 65 
presence in the environment has been attributed to the discharge of hospital 66 
effluents (Gómez-Canela et al. 2014, Langford &Thomas 2009, Santos et al. 67 
2013, Verlicchi et al. 2010), domestic water (Rabiet et al. 2006) and effluents 68 
from Wastewater Treatment Plants (WWTP) (Gómez-Canela et al. 2012, 69 
Santos et al. 2013, Verlicchi et al. 2012), but to date, no attention has been paid 70 
to senior residences.  71 
In Europe and over the world, the phenomenon of aging and over-aging has 72 
led to societies where 15-20% of the population is over 65 years. Countries with 73 
aging populations have to increase their resources according to the demands of 74 
elderly people being necessary to ensure environmental sustainability and 75 
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public health. The homes for elderly people are infrastructures that articulate 76 
diverse services in response to biopsychosocial needs and have become 77 
popular in most European countries. Senior residences have a configuration of 78 
typically 50-150 individuals and provide lodging, meal services and health and 79 
social assistance. With an estimated consumption of 5-10 pills/patient, the total 80 
consumption of pharmaceuticals is of hundreds of milligrams. These 81 
compounds are excreted through urine of faeces and are released to the main 82 
urban grid without any type of treatment. There, waters are transported to the 83 
WWTP, which unable to eliminate the total load of pharmaceuticals, contribute 84 
to their release to receiving waters, posing the environment at risk (Figure 1). 85 
This problem is magnified all around the world due to the aging effect and the 86 
increased population established in senior residences. Thus, senior residences 87 
can represent a point source pollution of pharmaceuticals to the environment. 88 
The European Medicines Agency (EMEA) is an agency of the European 89 
Union (EU), responsible for the scientific evaluation, supervision and safety 90 
monitoring of medicines developed by pharmaceutical companies for use in the 91 
EU (European Medicines Agency (EMEA) 2006). Among other activities, they 92 
monitor the safety of medicines across their life cycle. In 2006, EMEA proposed 93 
the calculation of predicted environmental concentrations (PEC) to estimate the 94 
presence of pharmaceuticals in environmental waters and recommended to 95 
evaluate their risk when PEC values in surface water were equal or above the 96 
threshold value of 0.01 µg/L. This model takes into account the consumption of 97 
a specific drug, the excretion rates and the dilution factor in a particular region 98 
and permits to prioritize specific drugs with potential to cause pharmacological 99 
effects at specific water concentrations (Fick et al. 2010). The efficiency and 100 
applicability of the approach to determine the theoretical presence of 101 
pharmaceuticals in surface and wastewaters and to prioritize compounds for 102 
further monitoring has been demonstrated by the increasing number of research 103 
papers that use this methodology, as in Italy (Riva et al. 2015), Germany 104 
(Kümmerer &Al-Ahmad 2010), NW England (Booker et al. 2014), France 105 
(Besse et al. 2008), Catalonia (Franquet-Griell et al. 2015), The Netherlands 106 
(Oosterhuis et al. 2013) and Poland (Oldenkamp et al. 2013). Consumption or  107 
prescription data have demonstrated to be very valuable to determine the 108 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
occurrence of pharmaceuticals in the environment (Ortiz de García et al. 2013, 109 
van Nuijs et al. 2015). According to PEC values and toxicological information, it 110 
is then possible to determine the potential risk of pharmaceuticals in the 111 
environment (van Leeuwen &Vermeire 2007).  112 
Our hypothesis is that senior residences represent an important source, yet 113 
unexplored, of pharmaceuticals to the environment. In this study we propose an 114 
innovative scheme for the prioritization and risk management of 115 
pharmaceuticals discharged from senior residences based on consumption 116 
data, excretion, dilution and toxicity. We have followed EMEA guidelines for risk 117 
evaluation and we provide a list of pharmaceuticals consumed in high quantities 118 
in senior residences for which actions have to be implemented to reduce the 119 
environmental impact. 120 
 121 
Methodology 122 
Nursing homes studied 123 
Home for the elderly can be classified in different categories, each with its 124 
own specialization, particularity and functioning, as they host people with 125 
different types of illnesses. In this study we have selected 5 residences, 1 in 126 
France, 2 in Spain and 2 in Portugal. For comparability purposes among the 127 
three countries, the residences selected were all mixed model residences that 128 
had a high number of beds (>50), and that were located in urban areas. We 129 
considered as mixed model residences those that were either i) oriented to 130 
housing (i.e, for independent individuals that do not require help or assistance) 131 
and oriented to general impairment (for individuals with general loss of activities 132 
of daily function), or ii) oriented to housing, or general impairment, or specific 133 
types of diseases, and, in addition, provide services to other elderly people, 134 
such as day care center. The specific description of each residence (number of 135 
beds, type of facility and the annual water consumption) is indicated in Table 1.   136 
In each residence, we interviewed the manager and the head health 137 
professional to obtain information on the type of patients, sickness and level of 138 
impairment. All this information was key to define the typology of the residence 139 
and treatments performed. Then, each residence provided data on the 140 
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consumption of pharmaceuticals, as the number of pills, injections or other 141 
presentations of a specific drug, and their concentration. This information was 142 
compiled to identify the main pharmaceutical families administered and to 143 
calculate the total amount consumed (g per day) in each residence. To compare 144 
the consumption rates in the 5 residences, consumption data was normalized 145 
per patient so that data is given also in mg/d/inhab. Data correspond to 146 
consumptions in 2015, except for F1 and S1 which correspond to 2016.  147 
 148 
Estimation of the Predicted Environmental Concentrations  149 
PECs calculation were adapted from EMEA guidelines to determine the 150 
predicted concentrations in effluents from senior residences (PECres) and in 151 
rivers waters (PECriv). The former permitted to determine pharmaceuticals 152 
released to sewage waters according to high consumption and high excretion. 153 
On the other hand, PECriv considered the dilution in the sewage grid, the 154 
elimination in WWTP and the final dilution to receiving waters. PEC values are 155 
always given in µg/L.  156 
When calculating PECres, one of the main particularities that might affect 157 
the discharge of pharmaceuticals is the people wearing diapers. This implies 158 
that an inferior amount of pharmaceuticals than the one that was actually 159 
consumed will be discharged. This factor is included in the PECres formula:  160 
 161 
where, 162 
- Consumption (g/day) is the quantity of each pharmaceutical delivered in 163 
each senior residence. 164 
- Fexc is the excreted fraction of the unchanged drug, considering both 165 
urine and feces. When different values were reported in the bibliography, 166 
the highest one was used to consider the worst case scenario. Selected 167 
values ranged from negligible to >90%, depending on the compound. For 168 
those drugs whose values could not be found, no value was assigned.  169 
(eq. 1) 
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- Fdiap is the percentage of patients using diapers. In this study, we used 170 
the value of 50% as it represents the mean percentage of patients in 171 
senior residences using diapers.  172 
- Water consumption (L/d) is the water consumed in each residence per 173 
patient per day in 2015 (Table 1). 174 
- Inhab is the number of patients in each residence (Table 1). 175 
To evaluate the amount of pharmaceuticals discharged to the river waters, 176 
PECriv were estimated using the formula:  177 
 178 
where:  179 
- Fgrid is an expected 10% dilution of effluent waters from senior 180 
residences to the general sewage grid.  181 
- Fwwtp is the removal fraction in WWTP. Removal data was obtained 182 
from EPI Suite by Environmental Protection Agency (EPA) (EPA 2013). 183 
In the cases that no information was available a default value of 0 was 184 
used. 185 
- DF is the Dilution Factor from WWTP effluents to receiving water and 186 
was considered 75.73 for France, 25.92 for Spain and 61.23 for Portugal, 187 
as suggested by Keller (Keller et al. 2014). This differential dilution factor 188 
is used to better estimate PEC values according to the differences in 189 
river flows and dynamics among countries.  190 
For compounds with PECriv > 0.01 µg/L, as proposed by EMEA, the 191 
environmental hazards were calculated. Environmental risks to aquatic animals 192 
were estimated from the hazard quotient index (HQ) depicted in eq 3, using the 193 
estimated PECs and PNECs. The latter parameters was obtained from eq 4 194 
using reported ecotoxicological information from Ecotox (EPA), Drugbank or 195 
toxicological data sheets of Sigma-Aldrich, Sciencelab and Santa Cruz 196 
Biotechnology. As limited information for aquatic species ecotoxicity was found 197 
for most selected pharmaceuticals, PNEC was estimated using the lowest 198 
chronic LOEC or acute LC50s considering application factors (FA) of 100 and 199 
(eq. 2) 
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1000, respectively.  For those substances having only mammalian toxicological 200 
LD50 information an additional factor of 10 was used (i.e. FA=10000).   201 
)3.(eq
PNEC
PEC
HQ
i
i  202 
)4.(eq
FA
ENPOINTi
PNECi   203 
where PECi and PNEC are the estimated PEC and PNEC of contaminant i. 204 
Total hazard quotients HQTotal considering all selected pharmaceuticals were 205 
determined using the independent action concept (eq. 5) assuming that 206 
compounds act independently and that their effects were uncorrelated.  207 
  )5.(11
1
eqHQHQ
n
i
iTotal 

  208 
where HQi is the hazard quotient of compound i.  209 
 210 
Prioritization and risk evaluation 211 
As highlighted by Donnachie et al. (2016), it is not feasible to monitor all 212 
possible pharmaceuticals present in the environment and it is necessary to 213 
prioritize those that can represent the greatest threat (Donnachie et al. 2016). 214 
The consumption data permitted to prioritize compounds with the highest 215 
potential impact in river waters from France, Spain and Portugal. Figure 2 216 
exemplifies the workflow used, which is based on:  217 
(i) listing of pharmaceuticals according to the consumed data in each 218 
senior residence.  219 
(ii) calculation of the predicted concentration in the effluents of the senior 220 
residence (PECres) for all compounds and all residences. 221 
(iii) preselection of compounds with PECres > 10 µg/L to study their 222 
transport through the sewage grid and elimination in the WWTP. This 223 
concentration was tentatively selected to obtain the EMEA threshold 224 
level of 0.01 µg/L.  225 
(iv) calculation of PEC in river waters and ranking of compounds with 226 
PECriv higher than the 0.01 µg/L threshold level proposed by EMEA.   227 
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(v) toxicity evaluation using Daphnia magna or other species EC50 or 228 
LC50 values, depending on available data.  229 
(vi) selection of toxic compounds for which risk assessment is needed.  230 
All this information has been compiled in a database that allows the 231 
prioritization of those substances that may produce an environmental effect.  232 
 233 
Results 234 
Consumption of pharmaceuticals 235 
Figure 3 shows the consumption of pharmaceuticals in the 5 senior residences 236 
located in France, Spain and Portugal. The net total amount of pharmaceuticals 237 
ranged between 7.9 and 636 g/d, being the residences in Spain the ones with 238 
the highest consumption. According to the size of each residence, this 239 
corresponds to an average consumption per day per patient ranged from 48.3 240 
mg in F1 to 4889 mg in S2, although the levels were quite similar in S2 and P1 241 
and P2 (between 365 to 563 mg/inhab/d). Considering these quantities and 242 
taking into account that senior residences have become a living preference in 243 
many countries, the amounts of pharmaceuticals discharged to the sewage grid 244 
can become a real problem. For instance, there are >8000 senior residences in 245 
France, 5339 in Spain and 4787 in Portugal, which suggest that the estimated 246 
total consumption of pharmaceuticals from senior residences should not be 247 
disregarded in terms of contribution of pharmaceuticals load to the sewage grid 248 
and indirectly, to the environment. If we consider an average discharge of 100 249 
g/day in a median residence of 100 patients, that would mean than on a country 250 
base, from 478 to 800 kg of pharmaceuticals are discharged daily from senior 251 
residences in south-west Europe. These waters enter the sewage system in 252 
most countries, but eventually could be discharged without any treatment. Thus, 253 
the incurred risk is high.  254 
The number of pharmaceuticals consumed in each senior residence ranged 255 
between 133 and 164 (Table 1). Main pharmaceuticals consumed (> 1 g/d) in 256 
each of the five studied residence are also indicated in Table 1. These highly 257 
consumed drugs are similar to those detected in Iraq where paracetamol, 258 
amoxicillin and metformin has an annual consumption exceeding 1000 tonnes 259 
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per year (Al-Khazrajy &Boxall 2016). Observed differences in main consumed 260 
drugs in French, Spanish and Portuguese residences evidenced the different 261 
and specific treatments that patients can receive. A total of 397 common 262 
pharmaceuticals were consumed in the 5 senior residences studied, which 263 
belong to 90 therapeutic classes. Table SI1 shows all pharmaceuticals 264 
consumed in the 5 senior residences studied, indicating their Anatomical 265 
Therapeutic Chemical classification code (ATC) (WHO 2017). On the other 266 
hand, the main therapeutic classes consumed are indicated in Figure 3 and 267 
include antidiabetic, analgesic, antibiotics, and antiepileptics as the main 268 
treatments for the elderly. Figure 3 also reflects the high variability of each 269 
therapeutic group consumed in the 3 countries, suggesting specific 270 
pharmacological protocols per country or either specific medication according to 271 
impairment intrinsic of each patient or typology of residence. 272 
 273 
Flow of pharmaceuticals from senior residences to river waters 274 
Of the total number of pharmaceuticals consumed, we determined the PEC 275 
values in the effluents of senior residences. These calculations took into 276 
account that approximately half of the people living in the residences wear 277 
diapers. At a glance, this appears to minimize the problem of pharmaceuticals 278 
discharged into the wastewaters. However, it is important to note that this is 279 
adding up to another problem. If diapers are not properly disposed as biohazard 280 
waste in the senior residences, a similar amount of residues is polluting other 281 
places. 282 
The PECres varied from negligible to mg/L level (Table 2). Given the large 283 
number of pharmaceuticals administered, it is obvious that the ones consumed 284 
at the highest concentration and showing high excretion rates will have higher 285 
chances to reach surface waters. We initially set a threshold value of 10 µg/L for 286 
further risk evaluation. Such threshold was chosen because once these 287 
pharmaceuticals are discharged to the sewage grid, they are diluted, 288 
biodegraded in the WWTP to be finally diluted in receiving surface waters 289 
(Figure 1). This process of dilution and elimination of pharmaceuticals in WWTP 290 
would presumably lead to a concentration in river waters close to the EMEA 291 
value of 0.01 µg/L.  292 
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Among the total 397 pharmaceuticals administered in each residence, only 23 293 
had PECres > 10 µg/L, being 5 for F1, 18 for S1, 7 for S2, 9 for P1 and 10 for 294 
P2. Table 2 indicates the compounds with PECres > 10 µg/L for which PECriv 295 
was further studied.  296 
The PECriv are also indicated in Table 2 and ranged between 0.002 and 1.15 297 
µg/L, with the highest levels found in Spain due to the lower dilution factor. 298 
Comparing the PECres and PECriv, the concentrations estimated in river 299 
waters represent between 0.12-0.38% of the initially discharged by the effluents 300 
of the senior residence. This decrease in concentration is basically due to 301 
dilution in the sewage grid and dilution in river. The WWTP degradability for 302 
most of the compounds was very low and, thus, a high proportion of 303 
pharmaceuticals will be potentially discharged by the WWTP effluents to 304 
receiving waters. Figure 4 shows, using a double axis, this difference. For the 305 
studied compounds, there was very little variability on the percentage of 306 
pharmaceuticals detected in river in comparison to the effluents of the 307 
residences, indicating a similar behavior of all pharmaceuticals once discharged 308 
to the sewage grid.  309 
In France, 5 compounds with concentrations higher than 10 µg/L in PECres had 310 
PECriv between 0.002 to 0.203 µg/L, which represent 0.13±0.0002% of the 311 
concentration initially discharged, except for dabigatran which was highly 312 
biodegradable in WWTP and whose PEcriv was of 0.0023 µg/L. Therefore, 4 313 
compounds having PECriv > 0.01 µg/L included metformin, paracetamol, 314 
levetiracetam and amoxicillin.  315 
In both Spanish residences, 17 out of 18 compounds exceeded the EMEA 316 
threshold value (0.01 µg/L). PECriv ranged from 0.03 to 1.07 µg/L, except for 317 
macrogol which had PECriv from 4.59 to 46.2 µg/L. Macrogol is the international 318 
nonproprietary name for polyethylene glycol used primarily as laxative or also 319 
as excipient in many pharmaceutical products. It is consumed in high amounts 320 
in Spain (57-580 g/d in the 2 Spanish residences or from 0.5 to 5 g/inhab/d) and 321 
is rapidly excreted and poorly degraded in WWTP. This compound has never 322 
been monitored in surface waters. The relatively high PECriv levels are mainly 323 
attributed to the low biodegradability in the WWTP. Three compounds, namely 324 
alcaphor (urinary alkalinizer), megestrol (a steroidal progestin) and ibuprofen 325 
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(an anti-inflamatory) were highly degradable. Specifically, PECriv for alcaphor 326 
was of 0.0068 µg/L due to 94% elimination in the WWTP, suggesting that there 327 
would be no risk. In contrast, WWTP were only partially efficient in eliminating 328 
ibuprofen (29%) and megestrol (30%) but given the high PECres, 0.03 and 0.05 329 
µg/L, they would be expected to be found in river waters. Overall, in Spanish 330 
residences, compounds with the highest PECriv were macrogol, metformin, 331 
paracetamol, gabapentin and amoxicillin. The low dilution factor is mainly 332 
responsible for the high PECriv of these compounds, which exceeded the value 333 
of 0.5 µg/L.  334 
Finally, in Portugal 9 compounds in P1 and 10 in P2 had PECres > 10 µg/L 335 
(Table 2) and PECriv higher than the EMEA 0.01 µg/L, indicating that despite 336 
the high dilution factor compared to Spain (61.23 vs 25.92), the 337 
pharmaceuticals consumed in senior residences might contribute to river waters 338 
contamination. In Portugal, the compounds with the highest PECriv were 339 
macrogol, metformin, and piracetam.   340 
When estimating the PECriv for compounds with PECres < 10 µg/L, we 341 
observed that dilution in the sewage grid, elimination in the WWTP and dilution 342 
in river waters was not enough to eliminate those pharmaceuticals. We have 343 
then identified that compounds present in effluents from senior residences at 344 
concentrations lower than 10 µg/L would be presumably detected in river waters 345 
at levels of 0.01-0.02 µg/L. The following compounds should be considered as 346 
suspect compounds as they could be present in river waters at concentrations > 347 
0.01 µg/L: sulfamethoxazole, rifaximine, pentosane polysulfate sodique, 348 
omeprazole, valproic acid, trimethoprim, ketoconazole, carbidopa, donezepil, 349 
valsartan, sitaglipin, tramadol, ranitidine and acetylsalicylic acid.  350 
Considering the 3 countries, the most consumed drugs and for which the 351 
PECriv is higher than 0.01 µg/L proposed by EMEA are listed in Table 2. 352 
Altogether, 23 compounds of the 397 commonly administered in senior 353 
residences had PECres > 10 µg/L and PECriv > 0.01 µg/L. Of the 23 prioritized 354 
compounds, only 3 compounds were common in all countries: paracetamol, 355 
levetiracem and metformin. Compounds used both in Spain and Portugal are 356 
acetylsalicylic acid, gabapentin, pregabalin, carbidopa, furosemide and 357 
macrogol. The rest of the compounds are specific of a given country or even 358 
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residence, indicating that there is a wide variability on the pharmaceuticals 359 
administered to patients, even though most belong to the same family. Many of 360 
these compounds have been previously identified as most commonly detected 361 
in the environment. For instance, metformin has been previously identified as 362 
one of the main pharmaceuticals in wastewaters in The Netherlands 363 
(Oosterhuis et al. 2013). Similarly, Van Nuijs et al. detected metformin, 364 
valsartan and tramadol in sewage water with good correlation with prescribed 365 
values (van Nuijs et al. 2015). 366 
 367 
Prioritization of pharmaceuticals for further treatment and risk 368 
assessment 369 
Table 3 gives the physico-chemical characteristics of the prioritized 370 
pharmaceuticals according to PECriv. Most of them have high solubility and low 371 
logP, indicating that preferentially they will remain in water. Even though 372 
pharmaceuticals can be degraded in water (Carlsson et al. 2006), their 373 
continuous discharge, even at low concentrations, make these drugs 374 
recalcitrant and environmentally hazardous compounds. Because of the lack of 375 
a legislation that controls the levels of drug residues in discharges and in 376 
surface waters, is important to prioritize actions that minimize the impact of 377 
these pollutants on the environment. Thus, the theoretical evaluation of 378 
presence and risk can provide a new and simple to use tool to predict their 379 
presence in the environment so that remediation technologies can be 380 
implemented. These tools can be extrapolated to other areas with similar 381 
problems (e.g. kindergartens, hospitals, etc.).  382 
For the 23 prioritized compounds, we determined the aquatic toxicity using 383 
different organisms according to available data from the open bibliography 384 
(Table 4). Using this data and the maximum PECriv, the risk quotients were 385 
calculated. Table 4 includes aquatic and mammalian toxicological information 386 
and estimated PNECs and environmental hazards of the pharmaceutical most 387 
used in the SUDOE regions. From the 23 selected substances eight did not 388 
have toxicological information. From the remaining 16 environmental hazards 389 
ranged from 5 x 10-5 of gentamicin to 0.1 of paracetamol. The combined 390 
hazards of these 16 substances was 0.22, which is rather close to 1, the 391 
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benchmark for severe risk. From the 16 studied substances 6 of them amoxilin, 392 
glucosamide, ibuprofen, metformin, paracetamol and megestrol accounted for 393 
98% of risks. Note, however, that environmental hazards for glucosamide and 394 
megestrol were estimated from toxicity data reported on mammalian species, 395 
whose dosage was administered quite different (oral or injected) than that of 396 
aquatic organisms, thus for these two compounds there is more uncertainty 397 
than for the rest. 398 
When evaluating the environmental risks of pharmaceuticals consumed in 399 
Sweden, it was concluded there the risk for acute toxic effects with the current 400 
active pharmaceuticals was unlikely but highlight the lack of chronic ecotoxicity 401 
data for a correct evaluation of risk (Carlsson et al. 2006).  402 
Main risk compounds were analgesic and antipyretic drugs such as 403 
paracetamol, ibuprofen, metamizole and acetylcysteine, antibiotics such as 404 
amoxicillin and sulfamethoxazole, gabapentin and valproic acid for the 405 
treatment of epilepsy and neuropathic pain, sedative and hypnotic compounds 406 
such as clomethiazole and pharmaceuticals for the treatment of diabetes 407 
(metformin). However, it has been pointed out that there is a very little known 408 
information about long term effects of pharmaceuticals to aquatic organisms, in 409 
particular with respect to biological targets (Fent et al. 2006).  410 
 411 
Risk management 412 
The new "Urban Water Agenda 2030", addressed at the Leeuwarden 413 
Conference (02.2016), incorporates concerns about wastewater treatment by 414 
focusing on emerging contaminants to contribute to the achievement of the 415 
good chemical status of water bodies. The main objective is to prevent pollution 416 
of water by cities and to ensure the quality of water for urban use.  417 
In this study we have identified senior residences as a point source pollution of 418 
pharmaceuticals to the environment. The number of homes for elderly people is 419 
currently high and is expected to increase in the future. This is alarming 420 
because these establishments are a considerable source of emerging pollutants 421 
and, hitherto, there are no guidelines or information about the risk management 422 
of effluents, which are typically classified as domestic. Nonetheless, the World 423 
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Health Organization (Chartier 2014), alerts that although a large part of the 424 
wastewater from health-care facilities can be considered domestic (because 425 
they pose the same risks as domestic wastewater), depending on the service 426 
and tasks of the facility, these wastewaters might pose a higher risk. This is 427 
clearly the case for the homes for elderly people, where people consume a high 428 
number of pharmaceuticals. Therefore, regulations regarding the direct 429 
discharge in surface water and the indirect discharge in a municipal wastewater 430 
treatment plant, should consider possible onsite treatment, and water reuse. 431 
Onsite treatment could be an effective strategy to manage the risk of 432 
pharmaceuticals in the environment at this moment. Prioritization according to 433 
PECs would help in the implementation of focused monitoring and remediation 434 
technologies that consider only the most toxic compounds, which would ensure 435 
the effectiveness in the control and risk assessment of pharmaceuticals. A 436 
future avenue for this area would be to conduct cost-benefit analysis and 437 
economic and sociological studies to know the viability of this strategy.   438 
Risk management is a complex issue because it involves many and different 439 
types of stakeholders, such as environmental and health authorities, the 440 
pharmaceutical sector, water and waste industries, health practitioners, 441 
researchers, and elderly home managers and clients, as well as the general 442 
public. It must be ensured that environmental, social and economic objectives 443 
for risk management are clear and established early in the process, and that 444 
these are achieved. To facilitate this process, risk assessment and risk 445 
management should be integrated activities and should share a common 446 
requirement that is effective risk  communication (Naidu et al. 2016). 447 
A challenging issue in communicating the risks associated with pharmaceutical 448 
residues in wastewater is the unfamiliar nature of the concept, and that presents 449 
particular challenges to the risk communication strategy. The pharmaceutical 450 
residues in water can be considered emerging pollutants and, as could be 451 
expected, so can be the risks posed by these. These risks can be described as 452 
emerging risks, due to the fact that the evidence of the negative effects of the 453 
pharmacological pollution of water is relatively recent, sometimes controversial, 454 
and in part unknown (García-Santiago et al. 2016, Touraud et al. 2011). It is 455 
thus predictable that the familiarity with these risks should be particularly low. 456 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
For these reasons, related knowledge, attitudes and social representations 457 
have yet to be established. Social sciences approaches to risk perception of 458 
emerging risks suggests that, given such constraints, stakeholder’s responses 459 
on these topics are not pre-established, but will be constructed (Pidgeon et al. 460 
2011). This elaboration process starts in the inquiries about the topic, when the 461 
persons are for the first time confronted with these risks and they have to create 462 
an interpretation to deal with them (Lichtenstein &Slovic 2006) and are also 463 
influenced by the cultural and social dispositions people (Kahan 2009). For this 464 
reason, the key aspects of risk communication that are important to develop 465 
and maintain trust and “active transparency” in the case of risk and benefits of 466 
pharmaceuticals (namely openness through frequent dialogues, decisions 467 
based on the best available science, transparency, timeliness and 468 
responsiveness, should be taken into consideration about this topic (Bouder 469 
2011). Furthermore, campaigns to increase risk awareness should be initiated 470 
before any alarm episode (Barnett &Breakwell 2003) or crisis (Gaspar et al. 471 
2015). Otherwise, such episodes will dramatically influence the way society, in 472 
general, and stakeholders, in particular,  deem about this topic. 473 
 474 
Conclusions 475 
We have identified senior residences as a source of pharmaceuticals to surface 476 
waters at concentrations higher than 0.01 µg/L, which is the EMEA threshold for 477 
risk analysis. Depending on the size of the elderly people’s home, and taking 478 
into account the circumstances and medical treatments usually received, 479 
wastewaters contain pharmaceuticals in their effluents at concentrations > 10 480 
µg/L. Because these effluents are discharged to sewage grids and WWTP are 481 
mostly inefficient to eliminate pharmaceuticals, residues are discharged to river 482 
waters, thus contributing to water pollution. This effect, amplified by the large 483 
number of residences in the south west Europe, indicates the importance of 484 
controlling the discharges of pharmaceuticals form senior residences to 485 
minimize the impact on aquatic ecosystems. A protocol scheme and risk 486 
management actions foreseen should be used to implement focused monitoring 487 
and remediation technologies that consider the most toxic compounds to ensure 488 
effectiveness in the control and evaluation of the impact of pharmaceuticals. 489 
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Table 1. Number of pharmaceuticals administered in 2015.  505 
Residence 
Size 
Mixed facility 
type 
Water 
consumption 
(m3/year) 
Pharmaceuticals 
administered 
Compounds consumed at 
doses > 1000 mg/d Beds  
Day 
center  
F1 75 6 
Housing and 
general 
impairment 
4560 133 
Metformin 
 
S1 100 30 
Housing, 
general 
impairment 
psychiatric unit 
6679 164 
Macrogol 
Metformin 
Paracetamol 
Gabapentin 
Amoxicillin 
Cyanocobalamine (vitB12) 
Levetiracetam 
Alcaphor 
Levofloxacine 
S2 130 0 
Housing, 
general 
impairment 
7100 134 
Macrogol 
Metformine 
Levetiracetam 
Gabapentin 
P1 52 0 
Housing, 
general 
impairment 
5230 116 
Metformin 
Tiotropium bromide 
P2 61 0 
Housing, 
general 
impairment 
4859 146 
Macrogol 
Metformin 
Piracetam 
Levetiracetam 
 506 
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Table 2. Compounds prioritized in each residence according to consumption 507 
data, PECres > 10 µg/L and PECriv > 0.01 µg/L.  508 
Pharmaceutical 
Consumption 
(mg/day) 
PEC res (µg/L), 
50% of diapers 
PEC res (µg/L), 
with 10% DF 
PEC river 
(µg/L) 
Residence F1 
Metformin 1569 157 16 0.203 
Paracetamol 545 55 5.4 0.071 
Levetiracetam 540 54 5.4 0.076 
Dabigatran etexilate 167 17 1.7 0.002 
Amoxicillin 162 16 1.6 0.021 
Residence S1 
Macrogol 581336 12213 1221 46.20 
Metformin 13449 283 28 1.070 
Paracetamol 8316 175 17 0.662 
Gabapentin 7781 163 16 0.619 
Amoxicillin 6928 146 15 0.551 
Cyanocobalamine 2515 52.8 5.3 0.204 
Levetiracetam 1635 34.3 3.4 0.130 
Alcaphor 1414 29.7 3.0 0.007 
Levofloxacine 1397 29.4 2.9 0.111 
Megestrol 909 19.1 1.9 0.052 
Furosemide 890 18.7 1.9 0.070 
Gentamycine 699 14.7 1.5 0.056 
Ceftriaxone 592 12.4 1.2 0.047 
Ibuprofen 575 12.1 1.2 0.033 
Acetylsalicylique 556 11.7 1.2 0.044 
Pregabalin 490 10.3 1.0 0.039 
Ciprofloxacine 477 10.0 1.0 0.038 
Troxerutin 477 10.0 1.0 0.038 
Residence S2 
Macrogol 57729 1213 121 4.590 
Metformine 6367 134 13.4 0.506 
Levetiracetam 1740 36.6 3.7 0.138 
Gabapentin 1200 25.2 2.5 0.095 
Paracetamol 846 17.8 1.8 0.067 
Furosemide 672 14.1 1.4 0.053 
Troxerutin 671 14.1 1.4 0.053 
Residence P1 
Metformin 10823 378 37.8 0.610 
Tiotropium bromide 1480 51.6 5.2 0.083 
Levetiracetam 663 23.1 2.3 0.037 
Glucosamine 639 22.3 2.2 0.036 
Paracetamol 449 15.7 1.6 0.025 
Levodopa 410 14.3 1.4 0.023 
Acetylsalicylic acid 377 13.2 1.3 0.021 
Carbidopa 308 10.7 1.1 0.017 
Gabapentin 300 10.5 1.0 0.017 
Residence P2 
Macrogol 13125 164 16.4 0.26 
Metformin 4177 157 15.7 0.25 
Piracetam 3600 135 13.5 0.22 
Levetiracetam 1061 39.8 4.0 0.064 
Glucosamine 959 36.0 3.6 0.058 
Paracetamol 880 33.1 3.3 0.053 
Gabapentin 500 18.8 1.9 0.030 
Pregabalin 417 15.6 1.6 0.025 
Diosmin 315 11.8 1.2 0.019 
Furosemide 280 10.5 1.1 0.017 
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Table 3. Physico-chemical properties of prioritized pharmaceuticals according to PEC data. 509 
Pharmaceutical CAS num. 
Molecular 
Formula 
Mw 
Water 
solubility 
(mg/L) 
LogP 
Pv 
(mmHg, 
25°C) 
Half-life 
Acetylsalicylic acid 50-78-2 C9H8O4 180.2 5295 1.19 6.6e-05 31 min 
Amoxicillin 26787-78-0 C16H19N3O5S 365.4 3433 0.87 4.7e-17 61.3 min 
Carbidopa 28860-95-9 C10H14N2O4 226.2 3.9E+5 -0.13 2e-09 1-2 h 
Ceftriaxone 73384-59-5 C18H18N8O7S3 554.6 786.7 -1.99 5E-24 5.8-8.7 h 
Ciprofloxacin 85721-33-1 C17H18FN3O3 331.3 1.2E+4 0.28 3E-13 4 h 
Cyanocobalamin 68-19-9 C63H88CoN14O14P 1355.4 1.3E+4 1.87 NA 6 d 
Diosmin 520-27-4 C28H32O15 608.5 407.8 0.14 6E-27 NA 
Furosemide 54-31-9 C12H11ClN2O5S 330.7 149.3 2.03 3.1E-11 2 h 
Gabapentin 60142-96-3 C9H17NO2 171.2 4491 -1.1 3E-10 4–7 h 
Gentamicin 1403-66-3 C21H43N5O7 477.6 2E+5 -1.48 3.5E-18 3-3½ h 
Glucosamine 3416-24-8 C6H13NO5 179.2 1E+6 -2.2 2E-08 NA 
Ibuprofen 15687-27-1 C13H18O2 206.3 41.05 3.97 1.9E-04 2-4 h 
Levetiracetam 102767-28-2 C8H14N2O2 170.2 7910 -0.49 3.5E-06 6-8 h 
Levodopa 59-92-7 C9H11NO4 197.2 3E+5 -2.39 2.6E-10 1.5 h 
Levofloxacin 100986-85-4 C18H20FN3O4 361.4 3E+4 -0.39 9.8E-13 6-8 h 
Macrogol 25322-68-3 H–(OCH2CH2)n–OH NA 1E+5 NA NA NA 
Megestrol 3562-63-8 C22H30O3 342.5 27.02 3.41 3.5E-10 34 h 
Metformin 657-24-9 C4H11N5 129.2 1E+6 -2.64 7.6E-05 6.2 h 
Paracetamol 103-90-2 C8H9NO2 151.2 3E+4 0.46 2E-06 1-4 h 
Piracetam 7491-74-9 C6H10N2O2 142.2 8E+4 -1.54 6.4E-06 NA 
Pregabalin 148553-50-8 C8H17NO2 159.2 2E+4 -1.78 2E-09 6.3 h 
Tiotropium bromide 136310-93-5 C19H22BrNO4S2 472.4 3E+4 -1.76 1.9E-18 5-6 d 
Troxerutin 7085-55-4 C33H42O19 742.7 2E+4 -2.86 2.3E-34 NA 
  510 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
20 
 
 511 
Table 4. Reported aquatic (Aquatox µg/L) and mammalian( mg/kg) toxicological information for the 23 selected compunds, 512 
estimated Predicted No environmental concentration (PNEC, µg/L), hazard quotiont (HQ), % contribution to the total hazard of each 513 
compound (%). FA, application factor. PEC max, maximal predicted environmenta concentration (µg/L). NA, no data. 514 
Compound Aquatic Organisms Mammalian Tox FA PNEC PEC 
max 
HQ % 
Acetylsalicylic acid 360314 D. pulex; LC50 Oral, rat: LD50 = 200 1000 360.314 0.04 0.0001 0.05 
Amoxicillin 10000 D. magna LC50 NA 1000 10 0.55 0.055 22.58 
Carbidopa 35300 D. magna LC50 Oral  mice (LD50): 1750 1000 35.3 0.023 0.0007 0.27 
Ceftriaxone NA 
 
Intravenous rat LD50=2000  10000 280 0.047 0.0002 0.07 
Ciprofloxacin 1000000 
Dugesia japonica ; LC50; 
48h 
 intramuscular LD50 (mouse) 
258 1000 1000 0.038 <0.0001 0.02 
Cyanocobalamin NA 
 
NA 
 
NA 0.204 NA NA 
Diosmin NA 
 
NA 
 
NA 0.018 NA NA 
Furosemide 10000  Hydra vulgaris ;NOEC; 7d oral Rabit (LD50): 800  100 100 0.07 0.0007 0.28 
Gabapentin NA 
 
NA 
 
NA 0.618 NA NA 
Gentamicin 9599679.6 Danio rerio; LC50; 24h Intravenous, rat:  LD50: 96 1000 9599.68 0.055 <0.0001 0 
Glucosamine NA 
 
Oral mice: LD50=300 10000 3 0.057 0.019 7.8 
Ibuprofen 1600 D. magna, LC50 Oral mice: LD50=1255 1000 1.6 0.033 0.0206 8.46 
Levetiracetam 341000 D. magna, LC50 Intravenous DL50  (rat ):1038  1000 341 0.138 0.0004 0.16 
Levodopa 1780000 
 
Oral, rat: LD50 = 1780 10000 178 0.023 0.0001 0.05 
Levofloxacin 10000 D. magna; NOEC;48h DL50 Oral rat; 1478  100 100 0.111 0.0011 0.46 
Macrogol   >1000000  Oryzias latipes ; LC50; 24h NA 1000 NA 1840 NA NA 
Megestrol NA 
 
Intravenous (mouse) LD50: 56 10000 5.6 0.051 0.0091 3.74 
Metformin 3300 D. magna, EC50, 
reproduction 
oral Rabbit: LD50 = 350 100 33 1.069 0.0324 13.3 
Paracetamol 6400 D. magna, LC50 Oral rat: LD50 = 1944 1000 6.4 0.66 0.1031 42.33 
Piracetam NA 
 
DL50 Oral  mice, 2000 10000 200 0.216 0.0011 0.44 
Pregabalin > 1000000 D. magna, LC50 NA 
 
NA 0.038 NA NA 
Tiotropium bromide NA 
 
NA 
 
NA 0.082 NA NA 
Troxerutin NA 
 
NA 
 
NA 0.053 NA NA 
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Figure 1. Cycle of pharmaceuticals from their release in seniors’ residences to 515 
the river, with all the process that play a role in their transport and fate.  516 
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Figure 2. Workflow designed to prioritize pharmaceutical of environmental 520 
concern for which risk assessment and remediation actions.  521 
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Figure 3. Total daily consumption of pharmaceuticals in each residence, 525 
indicating the number of residents (N) and the families consumed in each 526 
establishemnt (pie diagrams).  527 
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Figure 4. Families of pharmaceuticals (in percentage) most widely consumed in 531 
residences from southwest Europe (France, Spain and Portugal). N indicates 532 
the number of pharmaceuticals dispensed for each family. Macrogol (laxative) is 533 
not represented as its consumption ranges from 13 to 580 g/d which would 534 
represent 86% of the total pharmaceuticals consumed.  535 
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Figure 5. PECres (grey, left axis) and PECriv (light grey, right axis) in each 540 
country (F1=France, S1 and S2, Spain and P1 and P2, Portugal). This 541 
represents a decrease in % of more than 99%.  542 
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